Stifel maintains Zimmer Biomet Holdings at Buy, raises price target to $140 from $125
Stifel kept its Buy rating on Zimmer Biomet Holdings and increased its price target to $140 from $125, suggesting a 35.6% upside from the Nov 13 close of $103.21. Recent analyst targets for the company range from $115 to $130.
How this was made

The 30-second read
Why it matters
The upgrade may prompt short covering and new buying, modestly lifting the stock.
Market read
A single analyst upgrade; modest relevance for traders watching the stock.
What to watch
Potential supply chain constraints or regulatory issues not addressed in the note.
Background
Stifel's analyst note updates the price target for Zimmer Biomet Holdings, a mid‑cap orthopedic device maker.
Ticker impact
Stifel raised its price target for Zimmer Biomet Holdings to $140 from $125, indicating a bullish outlook.
likely upward pressure as investors price in the higher target
The new target implies a 35.6% upside from the recent close, which may attract buying interest.
Market effects
May lift sentiment in the orthopedic device sector.
Limited to U.S. equities, no broader regional effect.
Minimal global impact beyond sector peers.
Counterpoint
Target raise could be premature if upcoming earnings miss expectations.
Key entities
- Analyst FirmStifel
Provided the upgraded price target.
- CompanyZimmer Biomet Holdings
Subject of the analyst rating change.

